New Protein Therapeutics-A Class of Antithrombotic Agents

Thrombosis is often overlooked despite the fact of blood clot being the common factor for heart attacks or strokes resulting in high death rates worldwide, especially in developing countries like India and China.

Although a broad range of preventive measures and anticoagulant and antiplatelet therapies are available, they are underused due to clinically relevant limitations. The major side effects of antiplatelets and anticoagulants are bleeding, manifestation of ‘drug induced thrombocytopenia’, including worsening of clotting and development of new clots that can lead to stroke, heart attack, deep vein thrombosis, or/and death.

The shortcomings of the current therapies drive us to adopt novel treatment approaches. We intend to come up with new protein therapeutics targeting principal point in the coagulation cascade. In this regard, we employ two means of arriving at the solution -

• Isolation and purification of active ingredients derived from natural sources
• Development of recombinant coagulation factors for therapeutic usage

We employ strategies to produce coagulation proteins with novel mechanisms of action for improved functional activity, with increased efficiency, increased potency, prolonged plasma half-lives, reduced immunogenicity and avoidance of secondary infections. Our approach holds promise for the efficient management of thrombosis, particularly in strokes and heart attacks.